SecBot SecBot

BBOT

BridgeBio Oncology Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001869105 Biotech & Drug Discovery
$2.66 −0.19 (−6.67%)
Oct 23 4:00 PM ET · prev $2.85
Market cap
$228.5M
Micro cap
Consensus
Buy
94% Buy or better · 17 analysts
Median target
$22.00
+727% · range $13.00–50.00
Next earnings
Nov 18
in 23 days · EPS est. −$0.66
1 year
−76.5%
from $11.31 · Oct 27
30 days
−30.2%
from $3.81
52-week range
$2.66–13.73
at the low
Avg volume 20D
596.7K
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 2 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 1/4 ·Next Earnings date, Nov 18, 2026
Strongest BEARISH BridgeBio Oncology Therapeutics, Inc. (BBOT) filed an EFFECT notice on September 10, 2026, indicating that…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 8 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    16 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.561 → −$0.662 over 90 days. 1 up, 7 down in 30 days.

  • TrendDOWNTREND

    53% below its 50-day average. New closing low $2.66 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCDOUBLED2,005,649$15.3M
STATE STREET CORPDOUBLED1,036,569$7.9M
ROYCE & ASSOCIATES LPTRIM384,941$2.9M
PRICE T ROWE ASSOCIATES INC /MD/TRIM300,000$2.3M
BNP PARIBAS FINANCIAL MARKETSDOUBLED191,152$1.5M
NORTHERN TRUST CORPADD186,482$1.4M
UBS Group AGDOUBLED114,655$873.7K
MILLENNIUM MANAGEMENT LLCTRIM105,480$803.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 94% rate it Buy or better
Strong Buy6Buy10Hold1Sell0Strong Sell0
12-month targets · 11 analysts

Price is below the lowest target. Median implies +727%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 21, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Oct 20, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform
Sep 11, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Sep 10, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Sep 9, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Sep 9, 2026Raymond James
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 21, 2026
Cobo Marc
Principal Accounting Officer
TAX W/H$544.04
Oct 1, 2026
Ben Yong
Chief Med & Dev Officer
TAX W/H$4.1K
Oct 1, 2026
Cobo Marc
Principal Accounting Officer
TAX W/H$496.44
Oct 1, 2026
Beltran Pedro
President and CEO
TAX W/H$4.1K
Oct 1, 2026
Elmelech Idan
COO & Principal Financial Ofcr
TAX W/H$1.4K
Sep 10, 2026
Cobo Marc
Principal Accounting Officer
AWARD9,038 sh
Sep 10, 2026
Cobo Marc
Principal Accounting Officer
TAX W/H$1.1K
Sep 10, 2026
Cobo Marc
Principal Accounting Officer
AWARD43,700 sh

Earnings setup

Estimates
Nov 18
reports in 23 days
−$0.66
EPS estimate, this quarter
−18%
estimate change, 90 days
1↑ 7↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.66-$0.80–-$0.49-0.5%$0.00
Next Q-$0.64-$0.72–-$0.49-1.3%$0.00
Current FY-$2.86-$4.61–-$1.98-0.4%$0.00
Next FY-$2.76-$5.52–-$1.86-1.5%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 Insider
Cobo Marc surrendered for taxes 203 shares
Principal Accounting Officer @ $2.68 ($544.04)
Oct 1, 2026 Insider
Ben Yong surrendered for taxes 1,047 shares
Chief Med & Dev Officer @ $3.94 ($4.1K)
Oct 1, 2026 Insider
Cobo Marc surrendered for taxes 126 shares
Principal Accounting Officer @ $3.94 ($496.44)
Sep 15, 2026 Short interest report
Short Interest: BBOT down 42% to 3.6M shares
Settlement 2026-09-15 | Days to cover: 4.36 | ≈4.49% of shares outstanding (est.)
Sep 11, 2026 SEC
BridgeBio Oncology Therapeutics, Inc. (BBOT) filed an EFFECT notice on September 10, 2026, indicating that its S-3…
EFFECT — Impact 5/10
Sep 9, 2026 SEC
BridgeBio Oncology Therapeutics, Inc. (BBOT) received SEC effectiveness on September 8, 2026 for its shelf…
EFFECT — Impact 4/10
Aug 15, 2026 SEC
BridgeBio Oncology Therapeutics (BBOT) saw a bearish institutional cluster in Q2 2026, with 4 sellers (including…
INST-CLUSTER — Impact 4/10
Aug 11, 2026 Press
BridgeBio Oncology Therapeutics (BBOT) awarded inducement stock grants to two new employees under its 2025 Inducement…
Impact 2/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
BBOT Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Sep 15, 2026
Short interest
Short Interest: BBOT down 42% to 3.6M shares
Settlement 2026-09-15 | Days to cover: 4.36 | ≈4.49% of shares outstanding (est.)
Sep 8, 2026
FDA
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage…
Sep 1, 2026
Press release
BBOT to Participate in Upcoming Investor Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage…
Aug 11, 2026
Contract
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage…
Jul 29, 2026
Earnings date
BBOT Q2 2026 Earnings Scheduled — 2026-07-29

SecBot reports

6 filings · 5 press releases · 1 bullish · 2 bearish · 3 neutral
All BBOT filing & press-release reports (11)